natgillin/translations-raw huggingface dataset:
Fluticasone: in a clinical study where ritonavir 100 mg capsules twice daily were co-administered with 50 μg intranasal fluticasone propionate (4 times daily) for 7 days in healthy subjects, fluticasone propionate plasma concentrations increased significantly, whereas the intrinsic cortisol levels decreased by approximately 86% (90% CI 82-89%).
Flutikazon: u kliničkom ispitivanju gdje su ritonavir 100 mg kapsule dvaput na dan istodobno primijenjene s 50 μg intranazalnog flutikazon propionata (4 puta na dan) tijekom 7 dana u zdravih ispitanika, značajno su porasle koncentracije flutikazon propionata u plazmi, dok su se razine intrinzičnog kortizola snizile približno 86% (90% CI 82-89%).
For the treatment of pulmonary arterial hypertension Sildenafil
Za liječenje plućne arterijske hipertenzije
The combination may result in increased risk of cardiovascular adverse event with salmeterol, including QT prolongation, palpitations and sinus tachycardia.
Kombinacija može rezultirati povećanim rizikom od kardiovaskularnog štetnog događaja sa salmeterolom, uključujući produljenje QT intervala, palpitacije i sinusnu tahikardiju.
Based on pharmacokinetic modeling, this dosage reduction of 75% is also applicable if patients receive rifabutin at doses other than 300 mg/day.
Na osnovu farmakokinetičkog modela, ovo sniženje doze od 75% primjenjivo je također ako bolesnici primaju rifabutin pri dozama različitim od 300 mg/dan.
The safety and efficacy of darunavir have not been established in patients with severe underlying liver disorders and darunavir is therefore contraindicated in patients with severe hepatic impairment.
Sigurnost i djelotvornost darunavira nije ustanovljena u bolesnika s teškim podležećim poremećajima jetre, stoga je darunavir kontraindiciran u bolesnika s teškim oštećenjem funkcije jetre.
Didanosine is to be administered on an empty stomach, thus it should be administered 1 hour before or 2 hours after boosted darunavir given with food.
Didanozin treba primijeniti na prazan želudac, odnosno treba ga primijeniti 1 sat prije ili 2 sata nakon pojačanog darunavira koji se uzima s hranom.
* these adverse drug reactions have not been reported in clinical trial experience with darunavir/cobicistat but have been noted with darunavir/ritonavir treatment and could be expected with darunavir/cobicistat too.
* ove nuspojave nisu prijavljene tijekom iskustva iz kliničkih ispitivanja s darunavirom/kobicistatom ali su zabilježene tijekom liječenja s darunavirom/ritonavirom, te se također mogu očekivati s darunavirom/kobicistatom.
Otherwise, there were no effects on mating or fertility with darunavir treatment up to 1,000 mg/kg/day and exposure levels below (AUC-0.5 fold) of that in human at the clinically recommended dose.
S druge strane, nije bilo učinka na parenje ili plodnost s liječenjem darunavirom do 1000 mg/kg/dan i razina izloženosti ispod onih (AUC - 0,5 puta) klinički preporučenih doza za ljude.
The absolute oral bioavailability of a single 600 mg dose of darunavir alone was approximately 37% and increased to approximately 82% in the presence of 100 mg twice daily ritonavir.
Apsolutna peroralna bioraspoloživost jednokratne doze od 600 mg samog darunavira bila je približno 37% i porasla na približno 82% u prisutnosti ritonavira od 100 mg dvaput na dan.
However, adjustment of the methadone dose may be necessary when concomitantly administered for a longer period of time.
Međutim, prilagodba doze metadona možda će biti potrebna kada se istodobno primjenjuju tijekom duljeg vremena.
Drug-induced hepatitis (e.g. acute hepatitis, cytolytic hepatitis) has been reported with darunavir.
Lijekom izazvan hepatitis (npr. akutni hepatitis, citolitički hepatitis) bio je prijavljen kod liječenja darunavirom.
Tablet dimension: 20 x 10 mm.
Dimenzija tablete: 20 x 10 mm.
Strong CYP3A inducers include e.g. carbamazepine, phenobarbital and phenytoin (see sections 4.4 and 4.5).
Snažni induktori CYP3A uključuju npr. karbamazepin, fenobarbital i fenitoin (vidjeti dijelove 4.4 i 4.5).
Renal impairment Results from a mass balance study with
Rezultati ispitivanja masene ravnoteže s
Sertraline 50 mg once daily
Sertralin 50 mg jedanput na dan
Following intravenous administration, the volume of distribution of darunavir alone was 88.1 ± 59.0 l (Mean ± SD) and increased to 131 ± 49.9 l (Mean ± SD) in the presence of 100 mg twice-daily ritonavir.
Nakon intravenske primjene, volumen distribucije samog darunavira bio je 88,1 ± 59,0 l (srednja vrijednost ± SD) i povećao se na 131 ± 49,91 (srednja vrijednost ± SD) u prisutnosti 100 mg ritonavira dvaput na dan.
Co-administration with strong CYP3A4 inhibitors is not recommended and caution is warranted, these interactions are described in the interaction table below (e.g. indinavir, azole antifungals like clotrimazole).
Istodobna primjena sa snažnim CYP3A4 inhibitorima se ne preporučuje i savjetuje se oprez, ove interakcije opisane su u tablici interakcija ispod (npr. indinavir, antifungalni azoli poput klotrimazola).
Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to combination antiretroviral therapy (CART).
Iako se smatra da je etiologija višeznačna (uključuje primjenu kortikosteroida, konzumaciju alkohola, tešku imunosupresiju, viši indeks tjelesne mase), slučajevi osteonekroze prijavljeni su naročito u bolesnika s uznapredovalom HIV bolešću i/ili s dugotrajnom izloženošću kombiniranoj antiretrovirusnoj terapiji (KART).
CALCIUM CHANNEL BLOCKERS Amlodipine
BLOKATORI KALCIJEVIH KANALA Amlodipin
The recommendations given for concomitant use of darunavir and other medicinal products may therefore differ depending on whether darunavir is boosted with ritonavir or cobicistat (see sections 4.3 and 4.4), and caution is also required during the first time of treatment if switching the pharmacoenhancer from ritonavir to cobicistat (see section 4.4).
Preporuke za istodobnu primjenu darunavira i drugih lijekova mogu se stoga razlikovati, ovisno o tome je li darunavir pojačan ritonavirom ili kobicistatom (vidjeti dijelove 4.3 i 4.4), a oprez je također potreban tijekom prvog liječenja ako se mijenja farmakokinetički pojačivač s ritonavira na kobicistat (vidjeti dio 4.4).
What you need to know before you take Darunavir Krka
Što morate znati prije nego počnete uzimati Darunavir Krka
Other tablet strengths and formulations of darunavir are available.
Dostupne su druge jačine tableta i oblici darunavira.
Based upon the safety profile of darunavir/ritonavir, the increase in darunavir exposure in the presence of rifabutin does not warrant a dose adjustment for darunavir/ritonavir.
Na temelju sigurnosnog profila darunavira/ritonavira, povišena izloženost darunaviru u prisustvu rifabutina ne zahtjeva prilagodbu doze darunavira/ritonavira.
The intravenous clearance of darunavir alone (150 mg) and in the presence of low dose ritonavir was 32.8 l/h and 5.9 l/h, respectively.
Intravenski klirens samog darunavira (150 mg) i u prisutnosti niske doze ritonavira bio je 32,8 l/h, odnosno 5,9 l/h.
Midazolam(oral) Triazolam
Midazolam (peroralni) Triazolam
Limited data are available in patients with HIV-1 clades other than B (see section 5.1).
Za bolesnike s drugim podtipovima HIV-1 osim B dostupni su ograničeni podaci (vidjeti dio 5.1).
The recommended dose of darunavir with low dose ritonavir for paediatric patients is based on body weight and should not exceed the recommended adult dose (600/100 mg twice daily or 800/100 mg once daily).
Preporučena doza darunavira s niskom dozom ritonavira za pedijatrijske bolesnike temelji se na tjelesnoj težini i ne smije prelaziti preporučenu dozu za odrasle (600/100 mg dvaput na dan ili 800/100 mg jedanput na dan).
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS Medicinal products by therapeutic areas
INTERAKCIJE I PREPORUČENE DOZE S DRUGIM LIJEKOVIMA
Darunavir Krka has only been used in limited numbers of patients 65 years or older.
Darunavir Krka je primjenjivan samo u ograničenog broja bolesnika u dobi od 65 godina ili starijih.
Therefore, no special precautions or dose adjustments are required in these patients (see sections 4.2 and 5.2).
Prema tome, u takvih bolesnika nisu potrebne posebne mjere opreza ili prilagodbe doze (vidjeti dijelove 4.2 i 5.2).
Cobicistat decreases the estimated creatinine clearance due to inhibition of tubular secretion of creatinine.
Kobicistat snižava procijenjeni klirens kreatinina zbog inhibicije tubularne skerecije kreatinina.
The doctor will inform you on how many Darunavir Krka tablets and how much ritonavir (capsules, tablets or solution) the child must take.
Liječnik će Vas informirati koliko Darunavir Krka tableta i koliko ritonavira (kapsula, tableta ili otopine) dijete mora uzeti.
However, increased methadone dose may be necessary when concomitantly administered for a longer period of time due to induction of metabolism by ritonavir.
Međutim, možda će biti potrebno povišenje doze metadona kada se istodobno primjenjuju tijekom duljeg vremena zbog indukcije metabolizma ritonavirom.
After therapy with darunavir has been initiated, patients should be advised not to alter the dosage, dose form or discontinue therapy without discussing with their health care provider.
Nakon početka terapije darunavirom, bolesnicima se mora savjetovati da ne mijenjaju doziranje, oblik doze niti da prekidaju terapiju, bez da o tome nisu razgovarali s liječnikom.
This protein binding is concentrationdependent indicative for saturation of binding.
Ovo je vezanje na protein ovisno o koncentraciji i pokazatelj je mogućnosti zasićenja vezanja.
Darunavir exhibits activity against laboratory strains and clinical isolates of HIV-1 and laboratory strains of HIV-2 in acutely infected T-cell lines, human peripheral blood mononuclear cells and human monocytes/macrophages with median EC50 values ranging from 1.2 to 8.5 nM (0.7 to 5.0 ng/ml).
Darunavir pokazuje aktivnost protiv laboratorijskih sojeva i kliničkih izolata HIV-1 te laboratorijskih sojeva HIV-2 u akutno inficiranim linijama T-stanica, humanim mononuklearnim stanicama iz periferne krvi i humanim monocitima/makrofagima s medijanom vrijednosti EC50 u rasponu od 1,2 do 8,5 nM (0,7 do 5,0 ng/ml).
During attempts to overcome the decreased exposure by increasing the dose of other protease inhibitors with low dose ritonavir, a high frequency of liver reactions was seen with rifampicin.
Tijekom pokušaja da se prevlada smanjenje izloženosti, povisujući dozu drugih inhibitora proteaze s niskom dozom ritonavira, došlo je do povišene učestalosti jetrenih reakcija s rifampicinom.
Both arms used a fixed background regimen consisting of tenofovir disoproxil fumarate 300 mg once daily and emtricitabine 200 mg once daily.
U obje skupine primijenjen je točno određeni osnovni režim koji se sastojao od tenofovirdizoproksilfumarata 300 mg jedanput na dan i emtricitabina 200 mg jedanput na dan.
In the rat, the combination of darunavir with ritonavir lead to a small increase in effect on RBC parameters, liver and thyroid and increased incidence of islet fibrosis in the pancreas (in male rats only) compared to treatment with darunavir alone.
U štakora, kombinacija darunavira s ritonavirom dovela je do malog povećanja učinka na parametre eritrocita, jetru i štitnjaču, te povećane incidencije fibroznih otočića u pankreasu (samo u mužjaka štakora) u usporedbi s liječenjem sa samim darunavirom.
These patients received darunavir/ritonavir 800/100 mg once daily in combination with other antiretroviral agents.
Ovi bolesnici su primili darunavir/ritonavir 800/100 mg jedanput na dan u kombinaciji s drugim antiretrovirusnim lijekovima.
There were no new clinically relevant safety findings compared with the known safety profile of darunavir/ritonavir in HIV-1 infected adults (see sections 4.2, 4.4 and 5.2).
Nisu zabilježeni novi klinički značajni sigurnosni podaci u usporedbi s poznatim sigurnosnim profilom darunavira/ritonavira u HIV-1 inficiranih odraslih bolesnika (vidjeti dijelove 4.2, 4.4 i
ANTIANGINA/ANTIARRHYTHMIC
ANTIANGINICI/ANTIARITMICI
Life-threatening and fatal drug interactions have been reported in patients treated with colchicine and strong inhibitors of CYP3A and P-glycoprotein (P-gp; see sections 4.3 and 4.5).
Po život opasne i fatalne interakcije lijekova prijavljene su u bolesnika liječenih kolhicinom i snažnim inhibitorima CYP3A i P-glikoproteina (P-gp; vidjeti dijelove 4.3 i 4.5).
Study was conducted with tenofovir disoproxil fumarate 300 mg once daily.
Ispitivanje je provedeno s tenofovirdizoproksilfumaratom 300 mg jedanput na dan.
There is an increased potential for sildenafil-associated adverse events (including visual disturbances, hypotension, prolonged erection and syncope).
Povećana je mogućnost od štetnih događaja povezanih sa sildenafilom (uključujući poremećaje vida, hipotenziju, produljenu erekciju i sinkopu).
The table below shows the efficacy data of the 48-week and 96-week analyses from the pooled POWER 1 and POWER 2 trials.
Tablica ispod prikazuje objedinjene podatke djelotvornosti nakon 48 i 96 tjedana u ispitivanjima POWER 1 i POWER 2.
Disopyramide Flecainide Lidocaine (systemic) Mexiletine Propafenone
Lidokain (sistemski) Meksiletin Propafenon
ethinylestradiol AUC  30% ethinylestradiol Cmin ND
etinilestradiol AUC  30% etinilestradiol Cmin NO
PHOSPHODIESTERASE, TYPE 5 (PDE-5) INHIBITORS
INHIBITORI FOSFODIESTERAZE, TIP 5 (PDE-5)
If switching the pharmacoenhancer from ritonavir to cobicistat, caution is required during the first two weeks of treatment with darunavir/cobicistat, particularly if doses of any concomitantly administered medicinal products have been titrated or adjusted during use of ritonavir as a pharmacoenhancer.
Ako se mijenja farmakokinetički pojačivač sa ritonavira na kobicistat, potreban je oprez tijekom prva dva tjedna liječenja darunavirom/kobicistatom, naročito ako su doze bilo kojeg od istodobno primijenjenih lijekova titrirane ili prilagođene tijekom primjene ritonavira kao farmakokinetičkog pojačivača.
For co-administration with strong CYP3A4 inhibitors, the same recommendations apply independent of whether darunavir is boosted with ritonavir or with cobicistat (see section above).
Za istodobnu primjenu sa snažnim CYP3A4 inhibitorima, odnose se iste preporuke, neovisno o tome je li darunavir pojačan s ritonavirom ili kobicistatom (vidjeti dio iznad).
Response (HIV-1 RNA < 50 copies/ml at week 24) %, n/N
Odgovor (HIV-1 RNK < 50 kopija/ml u 24. tjednu) %, n/N
Given that digoxin has a narrow therapeutic index, it is recommended that the lowest possible dose of digoxin should initially be prescribed in case digoxin is given to patients on boosted darunavir therapy.
Budući da digoksin ima uzak terapijski indeks, preporučuje se inicijalno propisati najnižu moguću dozu digoksina u slučaju kada se digoksin daje bolesnicima koji su na terapiji pojačanim darunavirom.
ANTINEOPLASTICS
ANTINEOPLASTICI
R(-) methadone AUC ↓ 16% R(-) methadone Cmin ↓ 15% R(-) methadone Cmax ↓ 24% darunavir /cobicistat may, in contrast, increase methadone plasma concentrations (see cobicistat SmPC).
R(-) metadon AUC ↓ 16% R(-) metadon Cmin ↓ 15% R(-) metadon Cmax ↓ 24% Nasuprot tome, darunavir/kobicistat može povećati koncentracije metadona u plazmi (vidjeti SmPC za kobicistat).
Patients with severe (Child-Pugh Class C) hepatic impairment.
Bolesnici s teškim oštećenjem funkcije jetre (Child-Pugh stadij C).
Cobicistat has not been studied in patients receiving dialysis, therefore, no recommendation can be made for the use of darunavir/cobicistat in these patients (see section 4.2).
Kobicistat nije ispitan u bolesnika na dijalizi, stoga se ne mogu dati preporuke za primjenu darunavira/kobicistata u ovih bolesnika (vidjeti dio 4.2).
A lower and upper clinical cut-off of 10 and 40 were identified.
Kao kliničke granice identificirani su 10-struko i 40-struko povećanje.
* DRV-RAMs: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V
* DRV-RAM: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V i L89V
Didanosine is to be administered on an empty stomach, thus it should be administered 1 hour before or 2 hours after darunavir/ritonavir given with food.
Didanozin treba primijeniti na prazan želudac, odnosno treba ga primijeniti 1 sat prije ili 2 sata nakon darunavira/ritonavira koji se uzima s hranom.
Darunavir demonstrates antiviral activity in vitro against a broad panel of HIV-1 group M (A, B, C, D, E, F, G) and group O primary isolates with EC50 values ranging from < 0.1 to 4.3 nM.
Darunavir pokazuje antivirusnu aktivnost in vitro protiv širokog panela HIV-1 skupine M (A, B, C, D, E, F, G) i skupine O primarno izolata s EC50 vrijednostima u rasponu od < 0,1 do 4,3 nM.
If there is a need to combine darunavir/ritonavir and carbamazepine, patients should be monitored for potential carbamazepine-related adverse events.
U slučaju potrebe za kombinacijom darunavira/ritonavira i karbamazepina, bolesnike se mora pratiti zbog potencijalnih nuspojava povezanih s karbamazepinom.
Increased plasma concentrations of lovastatin or simvastatin may cause myopathy, including rhabdomyolysis.
Povišene koncentracije lovastatina ili simvastatina u plazmi mogu uzrokovati miopatiju, uključujući rabdomiolizu.
Tablet dimension: 19.5 x 10 mm.
Dimenzija tablete: 19,5 x 10 mm.
C-darunavir trial in healthy volunteers showed that a majority of the radioactivity in plasma after a single 400/100 mg darunavir with ritonavir dose was due to the parent active substance.
Cdarunavir na zdravim dobrovoljcima pokazalo je da većinu radioaktivnosti u plazmi nakon jednostruke doze od 400/100 mg darunavira s ritonavirom treba pripisati osnovnoj djelatnoj tvari.
Darunavir Krka works by reducing the amount of HIV in your body.
Darunavir Krka djeluje tako da smanjuje količinu virusa HIV-a u Vašem tijelu.
Buspirone
Buspiron
Some side effects are typical for anti-HIV medicines in the same family as Darunavir Krka.
Neke su nuspojave tipične za lijekove protiv HIV-a koji spadaju u istu skupinu kao i Darunavir Krka.
Tell your doctor if you have diabetes.
- Upozorite liječnika ako imate šećernu bolest.
Your doctor will advise you how to deal with your symptoms or whether Darunavir Krka must be stopped.
Liječnik će Vam savjetovati što učiniti vezano uz pojavu simptoma i morate li prestati s uzimanjem lijeka Darunavir Krka.
Systemic corticosteroid effects including Cushing's syndrome and adrenal suppression have been reported in patients receiving ritonavir and inhaled or intranasally administered fluticasone.
Sistemski učinci kortikosteroida uključujući Cushingov sindrom i adrenalnu supresiju bili su prijavljeni u bolesnika koji su primali ritonavir i inhalirali ili intranazalno primijenili flutikazon.
Perphenazine,risperidone, thioridazine (to treat psychiatric conditions).
perfenazin, risperidon, tioridazin (za liječenje psihijatrijskih stanja).
Clonazepam
Klonazepam
Severe hepatic impairment could result in an increase of darunavir exposure and a worsening of its safety profile.
Teško oštećenje funkcije jetre može rezultirati povećanom izloženosti darunaviru i pogoršati njegov sigurnosni profil.
Imputations according to the TLOVR algorithm Based on a normal approximation of the difference in % response Clades A1, D, F1, G, K, CRF02_AG, CRF12_BF, and CRF06_CPX Difference in means
Na temelju normalne aproksimacije razlike u % odgovora Podtipovi A1, D, F1, G, K, CRF02_AG, CRF12_BF i CRF06_CPX Razlika srednjih vrijednosti
If a patient is already taking St John's wort, stop St John's wort and if possible check viral levels.
Ako bolesnik već uzima gospinu travu, potrebno je prestati s uzimanjem gospine trave i ako je moguće provjeriti razine virusa.
A clinical study utilising a cocktail of medicinal products that are metabolised by cytochromes CYP2C9, CYP2C19 and CYP2D6 demonstrated an increase in CYP2C9 and CYP2C19 activity and inhibition of CYP2D6 activity in the presence of darunavir/ritonavir, which may be attributed to the presence of low dose ritonavir.
Kliničko ispitivanje u kojem je korišten koktel lijekova koji se metaboliziraju putem citokroma CYP2C9, CYP2C19 i CYP2D6 pokazala su povišenje aktivnosti CYP2C9 i CYP2C19 i inhibiciju aktivnosti CYP2D6 uz prisustvo darunavira/ritonavira, što može biti pripisano prisustvu niske doze ritonavira.
Treatment with darunavir/cobicistat 800/150 mg during pregnancy results in low darunavir exposure (see section 5.2), which may be associated with an increased risk of treatment failure and an increased risk of HIV transmission to the child.
Liječenje darunavirom/kobicistatom od 800/150 mg tijekom trudnoće rezultira niskom izloženošću darunaviru (vidjeti dio 5.2), što može biti povezano s povećanim rizikom neuspjeha liječenja i povećanim rizikom prijenosa HIV-a na dijete.
At present the effect of raltegravir on darunavir plasma concentrations does not appear to be clinically relevant.
Za sada se čini da učinak raltegravira na koncentracije darunavira u plazmi nije klinički značajan.
Dose for adults who have not taken antiretroviral medicines before (your doctor will determine this)
Doza za odrasle koji prije nisu uzimali antiretrovirusne lijekove (to će odrediti Vaš liječnik)
The Darunavir Krka 400 or 800 milligram tablet is not for use in children younger than 3 years of age or weighing less than 40 kilograms.
Tableta lijeka Darunavir Krka od 400 miligrama ili 800 miligrama nije namijenjena za primjenu u djece mlađe od 3 godine ili tjelesne težine manje od 40 kilograma.
The table below shows the efficacy data of the 48 week analysis from the TITAN trial.
Tablica ispod prikazuje analizirane podatke djelotvornosti nakon 48. tjedna ispitivanja TITAN.
sum of active moieties of rifabutin (parent drug + 25-O-desacetyl metabolite)
zbroj aktivnih komponenti rifabutina (osnovni lijek + 25-Odesacetil metabolit)
It is important to talk to your doctor if you develop a rash.
Važno je da razgovarate s liječnikom ako se pojavi osip.
The type of food does not affect the exposure to darunavir (see sections 4.4, 4.5 and 5.2).
Vrsta hrane ne utječe na izloženost darunaviru (vidjeti dijelove 4.4, 4.5 i 5.2).
However, when HIV genotypic testing is not feasible, the darunavir/ritonavir once daily dosing regimen is recommended in HIV protease inhibitor-naïve paediatric patients and the twice daily dosing regimen is recommended in HIV protease inhibitor-experienced patients.
Međutim, kada testiranje genotipa HIV-a nije moguće provesti, preporučeni režim doziranja darunavira/ritonavira je jedanput na dan u pedijatrijskih bolesnika koji prethodno nisu uzimali inhibitore proteaze HIV-a i dvaput na dan, preporučeni režim doziranja u bolesnika koji su prethodno uzimali inhibitore proteaze HIV-a.
Up to same dose levels, there was no teratogenicity with darunavir in rats and rabbits when treated alone nor in mice when treated in combination with ritonavir.
Pri istim razinama doza, nije bilo teratogenosti s liječenjem darunavirom u štakora i kunića, a niti u miševa uz liječenje kombinacijom s ritonavirom.
Endocrine disorders uncommon hypothyroidism, increased blood thyroid stimulating hormone
Endokrini poremećaji manje često hipotireoza, povišen tiroidni stimulirajući hormon u krvi
Both arms used an Optimised Background Regimen (OBR) consisting of at least 2 antiretrovirals (NRTIs with or without NNRTIs).
Obje skupine bolesnika su primale optimizirani osnovni režim (OOR) liječenja koji se sastojao od najmanje 2 antiretrovirusna lijeka (NRTI sa ili bez NNRTI).
Flurazepam Midazolam (parenteral) Zoldipem
Midazolam (parenteralni) Zoldipem
Sedative/hypnotics are extensively metabolised by CYP3A.
Sedativi/hipnotici se opsežno metaboliziraju putem CYP3A.
Darunavir/ritonavir should be used during pregnancy only if the potential benefit justifies the potential risk (see sections 4.4, 4.6 and 5.2).
Darunavir/ritonavir se smije uzimati tijekom trudnoće samo ako potencijalna korist opravdava potencijalni rizik (vidjeti dijelove 4.4, 4.6 i 5.2).
Tell your doctor if you have haemophilia.
- Upozorite liječnika ako imate hemofiliju.
≥ 15 kg to < 30 kg
≥ 15 kg do < 30 kg
CALCIUM CHANNEL BLOCKERS
BLOKATORI KALCIJEVIH KANALA